Secondary Prevention
There is no content available at this time. Please check again later.
Relevant Content
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy
Financial Toxicity: Inequities and Impact on Cardiovascular Disease
Polypharmacy is common in cardiovascular (CV) care because guideline-direc...
Neighborhood Social Determinants of Health and Referral to Cardiac Rehabilitation: An Analysis of the Get With The Guidelines–Coronary Artery Disease Registry
Circulation: Population Health and Outcomes, Ahead of Print.
BACKGROU...
Cardiovascular Risk Reduction With GLP-1 RA Drugs
BACKGROU...
Circulation, Volume 154, Issue 1, Page 66-73, July 7, 2026.
GLP-1 (gl...
Metabolic and Safety Outcomes of Statin–Ezetimibe Versus High‐Intensity Statin in Older Patients
GLP-1 (gl...
Journal of the American Heart Association, Ahead of Print.
Background...
Hypertension Treatment Intentions: A Health Belief Model Analysis
Background...
Hypertension, Ahead of Print.
Researchers at Heart
Arteriosclerosis, Thrombosis, and Vascular Biology, Ahead of Print.
H...
Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance
H...
Circulation: Population Health and Outcomes, Ahead of Print.
BACKGROU...
July 2026 Stroke Highlights
BACKGROU...
Stroke, Volume 57, Issue 7, Page 1839-1839, July 1, 2026.
Treating Psychological Factors in Patients With Heart Disease: Where Have We Been, How Shall We Proceed?
Journal of the American Heart Association, Volume 15, Issue 12, June 16, 2...